[사진=셀트리온제약 제공]
Celltrion Pharmaceutical continued high strides despite a new coronavirus infection (Corona 19) last year, both sales and operating profit and net profit increased significantly. This is the highest performance since being incorporated into Celltrion Group.
It is evaluated that the growth of all business divisions, including chemicals and biopharmaceuticals, led to good performance.
Celltrion Pharmaceutical announced on the 25th that it recorded 23.360 billion won in sales, 23.6 billion won in operating profit, and 29.3 billion won in net income last year. Compared to the same period last year, sales increased 34.6%, operating profit and net profit increased 60.3% and 143.4%, respectively. Sales, operating profit, and net profit all recorded the highest levels since the incorporation of Celltrion Group (2009).
Celltrion Pharm cited the growth of all business divisions, including chemicals and biopharmaceuticals, as the driving force behind strong earnings. In particular, sales of global chemical products, which expanded in earnest from 3Q, were effective.
The representative item, Godex, a soy sauce solvent, posted the largest sales of a single item with sales of about 65.7 billion won. The sales of three antibody biosimilars, Remsima, Hezuma, and Truxima, also recorded 43.3 billion won, an increase of 14% compared to the same period last year. In addition, six kinds of global chemical drugs, including CT-G7, a treatment for HIV (human immunodeficiency virus), increased production and shipments, achieving sales of about 43 billion won.
The company plans to maximize the production efficiency of its major items and focus on expanding its earnings by reinforcing marketing, while preparing and managing new growth engines thoroughly.
ETC (prescription medicine) and OTC, including items newly incorporated into the product lineup, such as’Edalbi’,’Nesina’,’Actos’,’Whi2ben’, and’Albochill’ that secured sales rights at the end of last year. It plans to strengthen its targeting in the (general drug) market. Along with this, it is a strategy to put all efforts into the successful market establishment of’Remsima SC’, a subcutaneous injection-type autoimmune disease treatment recently launched in Korea.
An official from Celltrion Pharmaceutical said, “This year, we have secured a number of promising products such as’Remsima SC’, a new anti-diabetic treatment, and anti-hypertension treatment, so we expect to continue a higher growth level based on product competitiveness.”
©’Five-language global economic newspaper’ Ajou Economy. Prohibition of unauthorized reproduction and redistribution